Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.92 USD | +3.90% | +0.14% | -30.10% |
Financials (USD)
Sales 2024 * | 31.31M | Sales 2025 * | 31.62M | Capitalization | 739M |
---|---|---|---|---|---|
Net income 2024 * | -140M | Net income 2025 * | -153M | EV / Sales 2024 * | 24.7 x |
Net Debt 2024 * | 34.45M | Net cash position 2025 * | 239M | EV / Sales 2025 * | 15.8 x |
P/E ratio 2024 * |
-5.36
x | P/E ratio 2025 * |
-5.3
x | Employees | 140 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.67% |
Latest transcript on Tango Therapeutics, Inc.
1 day | +3.90% | ||
1 week | +0.14% | ||
1 month | -4.95% | ||
3 months | -39.51% | ||
6 months | -10.82% | ||
Current year | -30.10% |
Managers | Title | Age | Since |
---|---|---|---|
Barbara Weber
CEO | Chief Executive Officer | 67 | 17-02-28 |
Daniella Beckman
DFI | Director of Finance/CFO | 45 | 16-09-30 |
Jannik Andersen
CTO | Chief Tech/Sci/R&D Officer | - | 18-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Alexis Borisy
CHM | Chairman | 52 | 16-12-31 |
Mace Rothenberg
BRD | Director/Board Member | 67 | 21-02-28 |
Barbara Weber
CEO | Chief Executive Officer | 67 | 17-02-28 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.03% | 0 M€ | 0.00% | - | |
0.00% | 9 M€ | +9.86% | - | |
0.00% | 9 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 6.92 | +3.90% | 817,863 |
24-05-30 | 6.66 | -1.33% | 1,047,804 |
24-05-29 | 6.75 | -1.46% | 638,243 |
24-05-28 | 6.85 | -0.87% | 559,274 |
24-05-24 | 6.91 | -2.54% | 707,524 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-30.10% | 739M | |
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- TNGX Stock